• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by STERIS plc (Ireland)

    11/4/25 9:53:32 AM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    STERIS PLC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    G8473T100

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G8473T100


    1Names of Reporting Persons

    Massachusetts Financial Services Company
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,674,537.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,846,124.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,846,124.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    STERIS PLC
    (b)Address of issuer's principal executive offices:

    70 Sir John Rogerson's Quay, Dublin 2, Ireland D02 R296, Ireland
    Item 2. 
    (a)Name of person filing:

    Massachusetts Financial Services Company
    (b)Address or principal business office or, if none, residence:

    111 Huntington Avenue, Boston, MA 02199
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    G8473T100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,846,124 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    (b)Percent of class:

    4.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4,674,537

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4,846,124

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Massachusetts Financial Services Company
     
    Signature:Deepu Pylee
    Name/Title:Compliance Director
    Date:11/03/2025
    Get the next $STE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    7/15/2025$276.00Equal-Weight → Overweight
    Morgan Stanley
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    More analyst ratings

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Steris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00

    7/15/25 8:30:16 AM ET
    $STE
    Industrial Specialties
    Health Care

    Jefferies initiated coverage on Steris with a new price target

    Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

    5/29/25 8:18:41 AM ET
    $STE
    Industrial Specialties
    Health Care

    Steris upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

    10/24/24 6:28:31 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STERIS Announces Financial Results for Fiscal 2026 Second Quarter

    Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the second quarter of fiscal 2026 increased 10% to $1.5 billion compared with $1.3 billion in the second quarter of fiscal 2025. Constant currency organic revenue growth from

    11/5/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on December 18, 2025, to shareholders of record at the close of business on November 18, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and

    10/29/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025

    DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 6, 2025, either

    10/21/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Carestio Daniel A sold $38,449 worth of Ordinary Shares (159 units at $241.82), decreasing direct ownership by 0.31% to 51,096 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    10/8/25 4:34:21 PM ET
    $STE
    Industrial Specialties
    Health Care

    Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,669 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    10/3/25 4:53:06 PM ET
    $STE
    Industrial Specialties
    Health Care

    V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 26 units of Ordinary Shares, decreasing direct ownership by 0.36% to 7,195 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    10/3/25 4:52:33 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    View All

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    STERIS Announces Changes to Board of Directors

    David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

    5/11/21 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    SEC Filings

    View All

    SEC Form 10-Q filed by STERIS plc (Ireland)

    10-Q - STERIS plc (0001757898) (Filer)

    11/6/25 4:08:22 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STERIS plc (0001757898) (Filer)

    11/5/25 4:41:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by STERIS plc (Ireland)

    SCHEDULE 13G/A - STERIS plc (0001757898) (Subject)

    11/4/25 9:53:32 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/13/24 5:14:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:49:03 AM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:32:52 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Financials

    Live finance-specific insights

    View All

    STERIS Announces Financial Results for Fiscal 2026 Second Quarter

    Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the second quarter of fiscal 2026 increased 10% to $1.5 billion compared with $1.3 billion in the second quarter of fiscal 2025. Constant currency organic revenue growth from

    11/5/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on December 18, 2025, to shareholders of record at the close of business on November 18, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and

    10/29/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025

    DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 6, 2025, either

    10/21/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care